Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RallybioFRA:33M0 -1.42%18 Net Margin % is -3,904.72% as of Mar. 2026. GuruFocus rates FRA:33M0 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 941 Biotechnology companies, Rallybio ranks worse than 77.79% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Rallybio's Net Income for the
three
months ended in Mar. 2026 was €-8.28 Mil. Rallybio's Revenue for the
three
months ended in Mar. 2026 was €0.21 Mil. Therefore, Rallybio's net margin for the quarter that ended in Mar. 2026 was -3,904.72%.
The historical rank and industry rank for Rallybio's Net Margin % or its related term are showing as below:
FRA:33M0'
s Net Margin % Range Over the Past 10 Years
Min: -9084.12 Med: -5065.26 Max: -911.07
Current: -911.07
FRA:33M0's Net Margin % is ranked worse than 77.79% of 941
companies
in the Biotechnology industry
Industry Median: -89.56
vs FRA:33M0: -911.07
Rallybio (FRA:33M0) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Rallybio Net Margin % Related Terms
Rallybio Net Margin % Historical Data
* Premium members only.
The historical data trend for Rallybio's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:33M0 vs VRCA, HRTX, CSBR: Net Margin % Comparison
For the Biotechnology subindustry, Rallybio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rallybio Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rallybio's Net Margin % distribution charts can be found below:
* The bar in red indicates where Rallybio's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rallybio (FRA:33M0) has a Net Margin % of -3,904.72% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Rallybio and its competitors. According to the industry distribution chart, Rallybio ranks #732 out of 941 companies in the Biotechnology industry, placing it in the top 77.8%.
Is Rallybio's Net Margin % too high?
Rallybio's current Net Margin % is -3,904.72%. Based on the distribution chart, Rallybio ranks #732 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rallybio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rallybio's Net Margin % compare to VRCA and HRTX?
According to the Biotechnology industry distribution chart, Rallybio ranks #732 out of 941 companies for Net Margin %. This places Rallybio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Rallybio and its competitors. Rallybio's current Net Margin % is -3,904.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rallybio stock overvalued right now?
Rallybio (FRA:33M0) has a current Net Margin % of -3,904.72%. The current Net Margin % is -3,904.72%. Rallybio's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Rallybio (FRA:33M0), the current Net Margin % is -3,904.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
18GF Score
Get the complete analysis for FRA:33M0
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:33M0 has been successfully added to your 
